• IBI Ag

  Participated · Series A · Nov 2025

  IBI Ag is an Israeli agri-biotech company pioneering a platform that uses single-domain antibodies (nanobodies) to create highly selective biological insecticides. Adapted from human therapeutics and optimized for agriculture, its products introduce new modes of action that protect high-value crops from both sucking and chewing pests while sparing beneficial species. The firm positions its technology as a lower-ecological-footprint alternative to conventional chemicals, aiming to help farmers boost yields sustainably. With fresh Series A capital, IBI Ag plans to accelerate product development and advance regulatory filings on multiple bio-insecticide candidates. The company also intends to deepen its collaboration with strategic investor Corteva to speed commercialization. Founded by The Trendlines Group alongside Dr. Amir Ayali and Dr. Rony Oren Benaroya, IBI Ag has been supported by the Israel Innovation Authority since inception. Financial details beyond the recent $10 million raise were not disclosed.

• Mako

  Participated · Seed · Jun 2022

  MAKO develops Flightfilm, a shark-skin-inspired surface technology intended to reduce skin-friction drag on aircraft and thereby lower fuel burn and emissions. The company was previously known as MicroTau and is based in Australia. Its immediate plans following the Series A are to pursue certification, scale production and roll out Flightfilm commercially for in-service aircraft. MAKO raised AU$28 million (about US$20 million) in the Series A led by Virescent Ventures to fund those efforts. The article did not disclose revenue, user numbers, or other operating metrics. No further details on product deployment timelines or prior funding were provided.

• Sicona Battery Technologies

  Participated · Series A · Aug 2021

  Sicona develops silicon-carbon (SiCx) anode materials designed to increase lithium-ion battery energy density by more than 20% and enable charging speeds over 40% faster than conventional graphite, while remaining compatible with existing battery production lines. The company is targeting markets including electric vehicles, AI data centres, power tools, defense, robotics, and other high-performance battery applications. Sicona plans to validate its process at a Wollongong facility that will produce up to 230 tonnes per year for customer qualification and commercial sales, and has longer-term plans for a 6,500-tonne-per-year commercial plant with expansion potential to 26,500 tonnes per year. The ARENA grant will fund construction and operation of the initial commercial-scale facility and support workforce development and local industry partnerships. Sicona entered a May 2025 licensing and strategic partnership with Himadri that included an AU$17.5 million follow-on investment, demonstrating recent capital and commercial progress.

No current team members are available.